Dismay at Competition Commission’s decision on cystic fibrosis drug
High cost of game-changing Trikafta treatment triggered campaign by now dismayed activists seeking lower prices
12 December 2024 - 18:50
The Competition Commission’s announcement that it will not refer cystic fibrosis drug manufacturer Vertex to the Competition Tribunal has been met with dismay by health activists campaigning for lower prices.
Vertex’s triple combination product Trikafta has transformed the treatment of cystic fibrosis, a rare genetic disorder that leads to an over-production of mucus in patients’ lungs. But its high cost has rendered it unaffordable for most governments and insurers, and triggered an international campaign by activists pressing for lower prices...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.